Earnings ·
Neuronetics reports Q3 revenue of $42.0M and adjusted EBITDA of $1.9M
STIMNeuronetics, Inc.
Neuronetics reported third-quarter 2026 total revenue of $42.0 million, a 12.5% increase from the prior-year period, driven by a 20.1% rise in Greenbrook clinic revenue to $26.2 million. The company posted an adjusted EBITDA of $1.9 million compared to a loss of $4.7 million in Q3 2025 and reduced its net loss to $1.6 million from $9.4 million. Operating expenses decreased 13% to $21.3 million, while gross margin expanded to 52.2%. The company maintained its full-year 2026 revenue guidance of $160 million to $164 million and updated its operating expense outlook lower. Neuronetics operates in the interventional mental health industry, providing transcranial magnetic stimulation technology through its NeuroStar system and direct patient care via Greenbrook clinics.